The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

We are excited to partner with the team at Tollo, who bring in-depth scientific and medical knowledge in both the areas of muscle loss and chronic viral infections”, said Jason Lang, Vice President of ...